A detailed history of Marshall Wace, LLP transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 1,188,612 shares of ACAD stock, worth $20.4 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,188,612
Previous 2,774,353 57.16%
Holding current value
$20.4 Million
Previous $45.1 Million 59.43%
% of portfolio
0.02%
Previous 0.06%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$15.14 - $19.14 $24 Million - $30.4 Million
-1,585,741 Reduced 57.16%
1,188,612 $18.3 Million
Q2 2024

Aug 14, 2024

BUY
$14.62 - $18.42 $32.9 Million - $41.5 Million
2,251,940 Added 431.07%
2,774,353 $45.1 Million
Q1 2024

May 15, 2024

BUY
$17.79 - $30.86 $9.29 Million - $16.1 Million
522,413 New
522,413 $9.66 Million
Q3 2023

Nov 14, 2023

BUY
$20.84 - $33.47 $19.1 Million - $30.7 Million
916,903 Added 3689.45%
941,755 $19.6 Million
Q2 2023

Aug 14, 2023

BUY
$17.8 - $25.65 $442,365 - $637,453
24,852 New
24,852 $595,000
Q2 2022

Aug 15, 2022

SELL
$13.01 - $27.22 $6.93 Million - $14.5 Million
-532,557 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$20.94 - $27.5 $11.2 Million - $14.6 Million
532,557 New
532,557 $12.9 Million
Q1 2021

May 17, 2021

SELL
$25.02 - $54.99 $21.2 Million - $46.7 Million
-848,679 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$41.04 - $56.79 $11.7 Million - $16.2 Million
-285,133 Reduced 25.15%
848,679 $45.4 Million
Q3 2020

Nov 16, 2020

BUY
$36.42 - $57.0 $34 Million - $53.2 Million
933,686 Added 466.55%
1,133,812 $46.8 Million
Q2 2020

Aug 13, 2020

BUY
$39.26 - $52.73 $7.86 Million - $10.6 Million
200,126 New
200,126 $9.7 Million

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.78B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.